Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals

Diabetes
Bunpei KakinokiKen-ichi Saito

Abstract

Biological substances with neurotrophic activities, such as nerve growth factor (NGF) and monosialoganglioside GM1, have been considered as agents for diabetic peripheral neuropathy. Because recent studies have suggested that decreased availability of these substances might contribute to the pathogenesis of diabetic peripheral neuropathy, some clinical trials of NGF for diabetic peripheral neuropathy have been conducted and have led to mixed conclusions. The major reasons were its limited delivery to the nervous system and adverse effects induced by subcutaneous injection, which was necessary because NGF is a polypeptide. The current study investigates whether an orally active sialic acid derivative, MCC-257, has neuroprotective properties in diabetic peripheral nerves. MCC-257 augmented NGF activity in cultured dorsal root ganglia and PC12 (pheochromocytoma 12) cells. Treatment with MCC-257 elevated NGF levels in the sciatic nerve, accompanied by improvement in nerve conduction velocity in streptozotocin-induced diabetic animals. More importantly, MCC-257 ameliorated small fiber dysfunctions, including thermal hypoalgesia, substance P content, and histopathological innervation in the plantar skin of diabetic animals. Thus, the...Continue Reading

References

Jan 1, 1976·Advances in Experimental Medicine and Biology·B CeccarelliM Finesso
Dec 1, 1992·Brain Research Bulletin·T HashitaniH Nishino
Jun 26, 1987·Neuroscience Letters·B A SabelD G Stein
Jan 1, 1984·Advances in Experimental Medicine and Biology·R R AbrahamV Wynn
Jul 1, 1983·Acta diabetologica latina·G CrepaldiG Pagano
Jan 1, 1984·Journal of Neuroscience Research·B A SabelD G Stein
Oct 30, 1981·Science·F J RoisenG Yorke
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·T MutohN Fujiki
May 1, 1995·The European Journal of Neuroscience·P FernyhoughD R Tomlinson
Dec 1, 1994·The European Journal of Neuroscience·G R LewinL M Mendell
Jan 1, 1995·Journal of Neurochemistry·S SekimotoY Komiya
Apr 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·F Hory-LeeE Frank
Jun 1, 1996·Nature Medicine·P AnandD V Sinicropi
Aug 12, 1999·European Journal of Pharmacology·D A GreeneE L Feldman
Aug 18, 1999·The American Journal of Medicine·M A Mufson, R J Stanek
Apr 27, 2002·Annals of the New York Academy of Sciences·Andrea M VincentJames W Russell
Sep 28, 2002·Current Opinion in Neurology·Zachary Simmons, Eva L Feldman
Nov 28, 2002·JAMA : the Journal of the American Medical Association·Matthew J Sheetz, George L King

❮ Previous
Next ❯

Citations

Oct 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Thierry Bordet, Rebecca M Pruss
May 1, 2009·Nature Reviews. Drug Discovery·Nigel A CalcuttAnn Marie Schmidt
Sep 2, 2011·Biological & Pharmaceutical Bulletin·Tong Ho KangSun Yeou Kim
Jan 10, 2008·Neuro-degenerative Diseases·B FrickerF René
Oct 27, 2007·Expert Opinion on Biological Therapy·Simona MarzoratiCamillo Ricordi
Oct 15, 2010·La Revue de médecine interne·A-L FauchaisL Magy
Nov 22, 2014·Biomolecules & Therapeutics·Eunjung MoonSun Yeou Kim
Mar 10, 2010·Brain Research·Ahmad Mohammadi-FaraniMahmoud Ghazi-Khansari
Sep 8, 2009·Biochemical and Biophysical Research Communications·Itaru KyorakuMasamitsu Nakazato
Dec 9, 2014·Biological & Pharmaceutical Bulletin·Jong Hoon WonDae Kyong Kim
Jun 27, 2007·Diabetes, Obesity & Metabolism·Tamás Várkonyi, Peter Kempler
Mar 12, 2008·The Journal of Pain : Official Journal of the American Pain Society·Kazuhiro SugimotoMinoru Yasujima
Feb 12, 2013·European Journal of Pharmacology·Wakaba TsuchimochiMasamitsu Nakazato
Sep 2, 2008·Journal of Pharmacological Sciences·Maki K YamadaMitsutoshi Setou
Jan 15, 2014·Journal of Nutritional Science and Vitaminology·Kyung Ae LeeTae Sun Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.